To read the full story, subscribe or sign in.

BMS’ Opdivo greenlighted as first immunotherapy for first-line advanced gastric cancer in China

Sep. 1, 2021

Bristol Myers Squibb Co.’s Opdivo (nivolumab) is now the first and only immunotherapy for the first-line treatment of advanced gastric cancer in China.

BioWorld Regulatory Cancer China NMPA

Today's news in brief

BioWorld

BioWorld briefs for Jan 6, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 6, 2026.

AND-017 increases RBC and hemoglobin in sickle cell disease

BioWorld Science

Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Science in 2025: the best of the rest

BioWorld Science

A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.